Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients

被引:2
|
作者
van der Lee, Manon [1 ]
Sankatsing, Roaj
Schippers, Emile
Vogel, Martin
Faetkenheuer, Erd
van der Ven, Andre
Kroon, Frank
Rockstroh, Juegen
Wyen, Christoph
Baeumer, Anselm
de Root, Eric
Koopmans, Peter
Stroes, Erik
Reiss, Peter
Burger, David
机构
[1] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands
[2] Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands
[3] Acad Med Ctr, Dept Vasc Med, Amsterdam, Netherlands
[4] Univ Med Ctr Leiden, Dept Infect Dis, Leiden, Netherlands
[5] Univ Bonn, Dept Internal Med 1, D-5300 Bonn, Germany
[6] Univ Cologne, Dept Internal Med, Cologne, Germany
[7] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Gen Internal Med, Nijmegen, Netherlands
[8] Acad Med Ctr, Dept Infect Dis Trop Med & Aids, Amsterdam, Netherlands
关键词
D O I
暂无
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Lopinavir/ritonavir-containing antiretroviral therapy can cause hyperlipidaemia. However, most statins are contraindicated due to drug-drug interactions. Rosuvastatin undergoes minimal metabolism by CYP450, so no CYP450-based interaction with lopinavir/ritonavir is expected. This study explored the lipid-lowering effect of rosuvastatin and assessed the effect of lopinavir/ritonavir on the pharmacokinetics of rosuvastatin and vice versa. Methods: HIV-infected patients on lopinavir/ritonavir (viral load > 400 copies/ml) with total cholesterol (TC) > 6.2 mmol/l were treated with rosuvastatin for 12 weeks, starting on 10 ring once daily. If fasting target values (TC < 5.0 mmol/l, high-density lipoprotein-cholesterol > 1.0 mmol/l, low-density lipoprotein- cholesterol [LDL-c] < 2.6 mmol/l and triglycerides < 2.0 mmol/1) were not reached, rosuvastatin was escalated to 20 mg or 40 mg at week 4 and 8, respectively. Plasma lopinavir/ritonavir trough levels (C-min) were determined at week 0, 4, 8 and 12 and rosuvastatin C-min, at week 4, 8 and 12. Results: Twenty-two patients completed the study. Mean reductions in TC and LDL-c from baseline to week 4 (on rosuvastatin 10 mg once a day) were 27.6% and 31.8%, respectively. Lopinavir/ritonavir concentrations were not influenced by rosuvastatin (P=0.44 and 0.26, repeated-measures analysis). Median (interquartile range) rosuvastatin C-min, for 10 mg, 20 mg and 40 mg once daily were 0.97 (0.70-1.5), 2.5 (1.3-3.3) and 5.5 (3.3-8.8) ng/ml, respectively. Conclusions: Rosuvastatin appeared to be an effective statin in hyperlipidaemic HIV-infected patients. Lopinavir/ritonavir levels were not affected by rosuvastatin, but rosuvastatin levels unexpectedly appeared to be increased 1.6-fold compared with data from healthy volunteers. Until safety and efficacy have been confirmed in larger studies, the combination of rosuvastatin and lopinavir/ritonavir should be used with caution.
引用
收藏
页码:1127 / 1132
页数:6
相关论文
共 50 条
  • [31] Pharmacokinetics of Lopinavir-Ritonavir with and without Nonnucleoside Reverse Transcriptase Inhibitors in Ugandan HIV-Infected Adults
    Kityo, C.
    Walker, A. S.
    Dickinson, L.
    Lutwama, F.
    Kayiwa, J.
    Ssali, F.
    Nalumenya, R.
    Tumukunde, D.
    Munderi, P.
    Reid, A.
    Gilks, C. F.
    Gibb, D. M.
    Khoo, S.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (07) : 2965 - 2973
  • [32] Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children
    Neely, Michael N.
    Rakhmanina, Natella Y.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (04) : 808 - 809
  • [33] Pharmacokinetics of Lopinavir/Ritonavir and Efavirenz in Food Insecure HIV-Infected Pregnant and Breastfeeding Women in Tororo, Uganda
    Bartelink, Imke H.
    Savic, Rada M.
    Mwesigwa, Julia
    Achan, Jane
    Clark, Tamara
    Plenty, Albert
    Charlebois, Edwin
    Kamya, Moses
    Young, Sera L.
    Gandhi, Monica
    Havlir, Diane
    Cohan, Deborah
    Aweeka, Francesca
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (02): : 121 - 132
  • [34] Lopinavir population pharmacokinetics on HIV-infected pregnant women
    Bouillon-Pichault, M.
    Treluyer, J. M.
    Rey, E.
    Pons, G.
    Jullien, V.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 23 - 23
  • [35] Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings
    Matoga, Mitch M.
    Hosseinipour, Mina C.
    Aga, Evgenia
    Ribaudo, Heather J.
    Kumarasamy, Nagalingeswaran
    Bartlett, John
    Hughes, Michael D.
    ANTIVIRAL THERAPY, 2017, 22 (03) : 205 - 213
  • [36] Metabolic evaluation of HIV-infected patients receiving a regimen containing lopinavir/ritonavir (Kaletra™)
    Lafeuillade, A
    Hittinger, G
    Philip, G
    Lambry, W
    Jolly, P
    Poggi, C
    HIV CLINICAL TRIALS, 2004, 5 (06): : 392 - 398
  • [37] Dramatic interaction between levothyroxine and lopinavir/ritonavir in a HIV-infected patient
    Touzot, Maxime
    Le Beller, Christine
    Touzot, Fabien
    Louet, Agnes Lillo-le
    Piketty, Christophe
    AIDS, 2006, 20 (08) : 1210 - 1212
  • [38] Kaletra® (lopinavir/ritonavir), an antiretroviral therapy for HIV-infected individuals.
    Sham, HL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 229 : U1186 - U1186
  • [39] Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children
    Violari, Avy
    Lindsey, Jane C.
    Hughes, Michael D.
    Mujuru, Hilda A.
    Barlow-Mosha, Linda
    Kamthunzi, Portia
    Chi, Benjamin H.
    Cotton, Mark F.
    Moultrie, Harry
    Khadse, Sandhya
    Schimana, Werner
    Bobat, Raziya
    Purdue, Lynette
    Eshleman, Susan H.
    Abrams, Elaine J.
    Millar, Linda
    Petzold, Elizabeth
    Mofenson, Lynne M.
    Jean-Philippe, Patrick
    Palumbo, Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (25): : 2380 - 2389
  • [40] Simultaneous Population Pharmacokinetic Model for Lopinavir and Ritonavir in HIV-Infected Adults
    José Moltó
    Manuel José Barbanoj
    Cristina Miranda
    Asunción Blanco
    José Ramón Santos
    Eugenia Negredo
    Joan Costa
    Pere Domingo
    Bonaventura Clotet
    Marta Valle
    Clinical Pharmacokinetics, 2008, 47 : 681 - 692